These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26466344)

  • 1. Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
    Leduc V; Bourque L; Poirier J; Dufour R
    Pharmacogenet Genomics; 2016 Jan; 26(1):1-11. PubMed ID: 26466344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry.
    Roy G; Couture P; Genest J; Ruel I; Baass A; Bergeron J; Brisson D; Brunham LR; Cermakova L; Gaudet D; Khoury E; Laflamme N; Kennedy BA; Hegele RA; Drouin-Chartier JP
    Can J Cardiol; 2022 Mar; 38(3):311-319. PubMed ID: 34774719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.
    Medina MW; Gao F; Ruan W; Rotter JI; Krauss RM
    Circulation; 2008 Jul; 118(4):355-62. PubMed ID: 18559695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.
    Yu CY; Theusch E; Lo K; Mangravite LM; Naidoo D; Kutilova M; Medina MW
    Hum Mol Genet; 2014 Jan; 23(2):319-32. PubMed ID: 24001602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.
    Leduc V; Théroux L; Dea D; Dufour R; Poirier J
    J Mol Neurosci; 2016 Jan; 58(1):109-19. PubMed ID: 26541602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
    Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.
    Burkhardt R; Kenny EE; Lowe JK; Birkeland A; Josowitz R; Noel M; Salit J; Maller JB; Pe'er I; Daly MJ; Altshuler D; Stoffel M; Friedman JM; Breslow JL
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2078-84. PubMed ID: 18802019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
    Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
    Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of
    Liu Z; Zhou Y; Jin M; Liu S; Liu S; Yang K; Li H; Luo S; Jureti S; Wei M; Fu Z
    PeerJ; 2024; 12():e18144. PubMed ID: 39351366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
    Akadam-Teker B; Kurnaz O; Coskunpinar E; Daglar-Aday A; Kucukhuseyin O; Cakmak HA; Teker E; Bugra Z; Ozturk O; Yilmaz-Aydogan H
    Gene; 2013 Oct; 528(2):93-8. PubMed ID: 23933271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
    O'Neill FH; Patel DD; Knight BL; Neuwirth CK; Bourbon M; Soutar AK; Taylor GW; Thompson GR; Naoumova RP
    Arterioscler Thromb Vasc Biol; 2001 May; 21(5):832-7. PubMed ID: 11348882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
    Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
    Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of HMGCR alternative splicing in statin efficacy.
    Medina MW; Krauss RM
    Trends Cardiovasc Med; 2009 Jul; 19(5):173-7. PubMed ID: 20005478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
    Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
    Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese.
    Hiura Y; Tabara Y; Kokubo Y; Okamura T; Goto Y; Nonogi H; Miki T; Tomoike H; Iwai N
    Circ J; 2010 Mar; 74(3):518-22. PubMed ID: 20145341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.